GlassScriptPhysician profile
Michelle D Beaupre
NPI 1760752091
$10,403.06
in general payments reported to CMS, 2019-2025
23 companies · $2,999 in 2025
The $2,999 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,133 · 2022: $1,672 · 2023: $2,330 · 2024: $2,269 · 2025: $2,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,544 · Education: $54.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,543.65 |
| Education | $54.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,788.02 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,243.84 | 2021-2025 | Rexulti, Abilify Mycite |
| Supernus Pharmaceuticals, INC. | $1,173.43 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $883.97 | 2021-2025 | Trintellix |
| Abbvie INC. | $858.07 | 2021-2025 | |
| Corium, LLC | $677.56 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $599.97 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $495.58 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $451.86 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Lundbeck LLC | $436.87 | 2021-2025 | Rexulti |
| Alkermes, INC. | $393.84 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $391.74 | 2021-2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $279.29 | 2022-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $245.53 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $108.22 | 2022-2025 | Austedo Xr, Austedo Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $101.39 | 2022-2025 | Ingrezza |
| Neos Therapeutics, LP | $69.57 | 2022-2025 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $63.52 | 2024-2025 | Xelstrym, Secuado |
| Eisai INC. | $57.51 | 2021 | |
| Adlon Therapeutics L.P. | $31.89 | 2021 | |
| Harmony Biosciences LLC | $22.58 | 2023 | Wakix |
| Sage Therapeutics, LLC | $15.65 | 2021 | |
| Merck Sharp & Dohme LLC | $13.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Beaupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.